(Q48293570)

English

The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis. (English)

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

experimental autoimmune encephalomyelitis

0 references

multiple sclerosis

0 references

1

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

author name string

N Tabibzadeh

2

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

A Martin

3

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

E S Ventura

4

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

J H Ware

5

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

G X Zhang

6

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

J L Parr

7

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

A R Kennedy

8

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

A M Rostami

9

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

publication date

1 December 2006

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

12

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

6

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

688-697

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

Lessons from 10 years of interferon beta-1b (Betaferon/Betaseron) treatment

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Lipoatrophy in patients with multiple sclerosis on glatiramer acetate

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Are statins a treatment option for multiple sclerosis?

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

T cells, cytokines, and autoantigens in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Chemopreventive agents: protease inhibitors.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Synthetic peptide mimics of the Bowman-Birk inhibitor protein.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Two nuclear mutations that block mitochondrial protein import in yeast

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Human mast cells release metalloproteinase-9 on contact with activated T cells: juxtacrine regulation by TNF-alpha

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Requirement for endocytic antigen processing and influence of invariant chain and H-2M deficiencies in CNS autoimmunity

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Matrix metalloproteinases in inflammatory demyelination: targets for treatment

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Matrix metalloproteinases in neuroinflammation

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Inhibition of matrix metalloproteinase-1 activity by the soybean Bowman-Birk inhibitor

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2.

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Combination therapy for multiple sclerosis: the treatment strategy of the future?

1 reference

https://api.crossref.org/works/10.1177%2F1352458506070769

21 January 2018

Identifiers

10.1177/1352458506070769

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

1 reference

Europe PubMed Central

10 February 2018

http://europepmc.org/abstract/MED/17262995

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48293570&oldid=1459931271"